{"blog": [], "keywords": [{"value": "Sarepta Therapeutics Inc.", "name": "organizations", "rank": "1", "is_major": "N"}, {"value": "Muscular Dystrophy", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/05/26/business/fda-is-said-to-delay-decision-on-duchenne-muscular-dystrophy-drug.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "345", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The news caused a sharp rise in the stock of Sarepta Therapeutics, the maker of the drug, as some investors saw a hint of approval in the development.", "pub_date": "2016-05-26T00:00:00Z", "news_desk": "Business", "headline": {"main": "F.D.A. Is Said to Delay Decision on Duchenne Muscular Dystrophy Drug"}, "print_page": null, "snippet": "The news caused a sharp rise in the stock of Sarepta Therapeutics, the maker of the drug, as some investors saw a hint of approval in the development.", "_id": "57459d3638f0d821f0cf8b08", "slideshow_credits": null, "abstract": null}